Showing results (211-220 of 226) with videos related to

Sort By:
Pageof 23
The Journal of Thoracic and Cardiovascular Surgery|January 22, 2009
Impaired neuroanatomic development in infants with congenital heart diseaseKazuhiro Watanabe, Mie Matsui, Junko Matsuzawa, et al.
Annals of the Rheumatic Diseases|July 4, 2015
The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progressionTatsuya Atsumi, Kazuhiko Yamamoto, Tsutomu Takeuchi, et al.
Journal of the American Heart Association|October 8, 2021
Dual Antiplatelet Therapy Using Cilostazol in Patients With Stroke and Intracranial Arterial StenosisShinichiro Uchiyama, Kazunori Toyoda, Katsuhiro Omae, et al.
Annals of the Rheumatic Diseases|February 4, 2017
Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trialTatsuya Atsumi, Yoshiya Tanaka, Kazuhiko Yamamoto, et al.
Stroke|August 18, 2021
Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com TrialHaruhiko Hoshino, Kazunori Toyoda, Katsuhiro Omae, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|May 20, 2016
Higher Hemoglobin A1c After Discharge Is an Independent Predictor of Adverse Outcomes in Patients With Acute Coronary Syndrome　- Findings From the PACIFIC RegistryKeiji Noguchi, Mamoru Sakakibara, Naoya Asakawa, et al.
International Journal of Cardiology|February 13, 2018
The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillationHiroaki Shimokawa, Takeshi Yamashita, Shinichiro Uchiyama, et al.
The Tohoku Journal of Experimental Medicine|December 2, 2016
Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial FibrillationTakanori Ikeda, Hirotsugu Atarashi, Hiroshi Inoue, et al.
Ebiomedicine|October 27, 2015
The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group StudyNaohisa Hosomi, Yoji Nagai, Tatsuo Kohriyama, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|September 11, 2013
Rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke: the Japan Statin Treatment Against Recurrent Stroke (J-STARS)Yoji Nagai, Tatsuo Kohriyama, Hideki Origasa, et al.
Pageof 23